CD38 MCN | Fold vs Control ± SE (n = 3) | |||
---|---|---|---|---|
Dose (nM) | ||||
1 | 10 | 100 | 1000 | |
Retinoid | ||||
ATRA | 1.49 ± 0.07 | 1.60 ± 0.05 | 1.63 ± 0.07 | 1.67 ± 0.05 |
9-cis-RA | 1.11 ± 0.02 | 1.43 ± 0.02 | 1.77 ± 0.08 | 1.93 ± 0.02 |
13-cis-RA | 1.28 ± 0.06 | 1.50 ± 0.06 | 1.68 ± 0.10 | 1.71 ± 0.08 |
4-HPR | 1.11 ± 0.02 | 1.15 ± 0.02 | 1.20 ± 0.02 | 1.66 ± 0.19 |
2-way ANOVA | ||||
Dose | p = 0.0001 | |||
Retinoid | p < 0.0001 | |||
Tukey Kramer | ||||
Dose | p < 0.01 | 1 nM vs 10 nM | ||
1 nM vs 100 nM | ||||
1 nM vs 1000 nM | ||||
Retinoid | p < 0.01 | 4-HPR vs ATRA | ||
4-HPR vs 9-cis RA | ||||
4-HPR vs 13-cis RA | ||||
CD69 MCN | Fold vs Control ± SE (n = 3) | |||
Dose (nM) | ||||
1 | 10 | 100 | 1000 | |
Retinoid | ||||
ATRA | 1.29 ± 11.0 | 1.27 ± 10.5 | 1.40 ± 0.14 | 1.46 ± 0.15 |
9- cis -RA | 1.07 ± 3.4 | 1.27 ± 8.2 | 1.59 ± 0.16 | 1.64 ± 0.15 |
13- cis -RA | 0.99 ± 4.0 | 1.12 ± 3.4 | 1.24 ± 0.08 | 1.33 ± 0.11 |
4-HPR | 0.85 ± 6.2 | 0.86 ± 3.3 | 0.94 ± 0.04 | 1.08 ± 0.04 |
2-way ANOVA | ||||
Dose | p = 0.0001 | |||
Retinoid | p < 0.0001 | |||
Tukey Kramer | ||||
Dose | p < 0.01 | 1 nM vs 100 nM | ||
1 nM vs 1000 nM | ||||
Retinoid | p < 0.01 | 4-HPR vs ATRA | ||
4-HPR vs 9-cis-RA | ||||
4-HPR vs 13-cis-RA |